IDNA

iShares Genomics Immunology and Healthcare ETF [IDNA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IDNA Stock Summary

Top 10 Correlated ETFs

IDNA

Top 10 Correlated Stocks

IDNA

In the News

IDNA Financial details

Company Rating
-
Market Cap
137.39M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
0.12
Dividend %
1.01%
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-2.94%
SMA50
13.79%
SMA100
10%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
17.33-25.518
52W High
+38.62%
52W Low
+103.85%
RSI
63
Rel Volume
0.57
Avg Volume
44.71K
Volume
25.65K
Perf Week
7.8%
Perf Month
7.32%
Perf Quarter
19.25%
Perf Half Y
28.64%
-
-
-
-
Beta
1.15
-
-
Volatility
0.75%, 0.86%
Prev Close
3.12%
Price
34.655
Change
2.91%

IDNA Financial Performance

IDNA Dividend History

IDNA Frequently Asked Questions

What is iShares Genomics Immunology and Healthcare ETF stock symbol ?

iShares Genomics Immunology and Healthcare ETF is a US stock and trading under the symbol IDNA

What is iShares Genomics Immunology and Healthcare ETF stock quote today ?

iShares Genomics Immunology and Healthcare ETF stock price is $34.655 today.

Is iShares Genomics Immunology and Healthcare ETF stock public?

Yes, iShares Genomics Immunology and Healthcare ETF is a publicly traded company.

Something similar

Top by Market Cap
BRH.DE
VFINX
FXAIX
AAPL
VTI
Top Correlated ETFs
GNOM
HELX
WDNA
BIB
ARKG
Top Correlated Stocks
ARCT
CRSP
MGTX
RYTM
ANVS
Similar Market Cap
OPER
EXV2.DE
KTHN
BSC.L
BHG

Company Profile

Financial Services Asset Management
  • Volume Average 44.71K
  • Market Capitalization 137.39M
  • Headquarters US
  • IPO Date 2019-06-14

The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.